Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that
can be given to patients with advanced cancer. The safety of this drug combination will also
be studied.